Management of toxicities from immunotherapy: Available for download in PDF and PowerPoint
Haven't had much time lately? Here's what you may have missed in the last few weeks.
Sign-up to receive the OncologyPRO alert every 2 weeks.
13 Nov 2018
Neoadjuvant paclitaxel and carboplatin with dual HER2 blockade may be sufficient for the first-line treatment of women with HER2-positive stage II or...
12 Nov 2018
Adding elotuzumab to pomalidomide and dexamethasone improves the outcome of multiple myeloma patients with relapsed or refractory disease
09 Nov 2018
Long-term follow-up of patients who have undergone curative resection for hepatocellular carcinoma has identified several features associated with an...
08 Nov 2018
Patients with advanced ALK-positive non-small-cell lung cancer show overall and intracranial response to first-line or later-line lorlatinib therap
07 Nov 2018
When added to fluoropyrimidine plus bevacizumab, the use of irinotecan on first progression did not meet noninferiority criteria compared with upfront...
Commenting on the findings from the SOLO1 trial of maintenance olaparib in newly diagnosed patients with BRCA-mutated ovarian cancer and the CORAIL trial of lurbinectedin in platinum-resistant relapsed setting, both presented at ESMO 2018 Congress, Dr Ana Oaknin says that BRCA mutation in ovarian cancer is a very important prognostic factor that we cannot miss anymore. According to Dr Oaknin, the ovarian cancer trials shouldn’t be based just on platinum-free interval or number of previous lines of therapy, but on molecular characteristics as well. Platinum resistance terminology should be refined based on the concept that the patient is suitable or not to receive further platinum therapy.As we are moving in the field of personalised medicine, we need to move forward another kind of trial's design in order to improve patients outcome.
08-11 Nov 2018, Amsterdam, Netherlands
02-03 Nov 2018, Zurich, Switzerland
19-23 Oct 2018, Munich, Germany
28-29 Sep 2018, Valencia, Spain
19-20 Sep 2018, Singapore, Singapore
14-15 Sep 2018, Paris, France
01-03 Sep 2018, Oxford, United Kingdom
20-23 Jun 2018, Barcelona, Spain
15-20 Jun 2018, Belgrade, Serbia
22-23 May 2018, Zurich, Switzerland
18-19 May 2018, Valencia, Spain
11-12 May 2018, Lugano, Switzerland
04-05 May 2018, Lugano, Switzerland
27-29 Apr 2018, Lugano, Switzerland
18-22 Apr 2018, Mexico City, Mexico
